W hile chimeric fusion genes resulting from balanced chromosomal translocations have long been recognized as "drivers" of acute myeloid leukemia (AML), their critical downstream mediators are incompletely understood. In particular, common effector programs that are shared by various leukemogenic fusion genes, and may thus represent attractive targets for therapeutic intervention, remain elusive. Carsten Müller-Tidow and colleagues now demonstrate that fusion oncoproteins such as RUNX1T1-RUNX1 (also known as AML1-ETO) and MLLT3-KMT2A (also known as MLL-AF9) contribute to AML development by upregulating the expression of a distinct subset of small nucleolar RNAs (snoRNAs) that promote leukemogenesis via enhanced formation of snoRNA ribonucleoprotein complexes, induction of rRNA methylation, increased protein translation, and possibly other mechanisms. This first investigation into the functional consequences of aberrant snoRNA expression in AML adds to the ever-expanding catalog of non-coding RNAs involved in myeloid leukemogenesis, and raises the intriguing possibility that snoRNA deregulation may be a unifying feature of this disease. Furthermore, these data provide a starting point for future studies of the mechanistic link(s) between different types of leukemogenic driver mutations and snoRNA expression and the potential of snoRNAs as tractable therapeutic targets. 
